Overview
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, also known as GVS-111) is a synthetic dipeptide-derived compound developed in 1996 at the Russian Academy of Medical Sciences. It was designed as a more potent and bioavailable successor to piracetam, the original racetam nootropic. Despite structural similarities to racetams, Noopept is pharmacologically distinct—it does not directly bind to acetylcholine receptors and operates through different molecular mechanisms.
Noopept is approved and prescribed in Russia and several CIS countries for cognitive disorders, traumatic brain injury recovery, and organic brain syndrome. It has been studied in both animal models and human clinical trials, with evidence supporting its effects on memory consolidation, learning enhancement, and neuroprotection. Its potency is estimated at 1,000 times that of piracetam on a per-milligram basis.
The compound's mechanism involves modulation of AMPA and NMDA glutamate receptors, upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), and antioxidant/anti-inflammatory neuroprotection. Unlike stimulant-type cognitive enhancers, Noopept does not significantly affect dopamine or norepinephrine systems, resulting in a clean cognitive enhancement without the anxiety, insomnia, or dependency associated with psychostimulants.
This guide reviews the pharmacology, clinical evidence, safety profile, and practical considerations for Noopept, drawing from both the Russian clinical research literature and international preclinical studies.
Quick facts
- Mechanism
- Dipeptide nootropic enhancing BDNF/NGF and glutamate signaling
- Primary use
- Cognitive Enhancement & Neuroprotection
- Evidence
- moderate
- FDA
- Not approved
- Route
- Oral or sublingual administration
- Typical results
- Improved memory consolidation and cognitive clarity reported within 1–3 weeks
Chemical information
Noopept (GVS-111) has the chemical name N-phenylacetyl-L-prolylglycine ethyl ester, a molecular mass of 318.37 g/mol, and the formula C₁₇H₂₂N₂O₄. It is a synthetic dipeptide analog structurally related to the endogenous cycloprolylglycine. The phenylacetyl group enhances lipophilicity and oral bioavailability, while the ethyl ester is hydrolyzed in vivo to release the active dipeptide.
How Noopept works
Noopept's cognitive effects are mediated through a multi-target mechanism that primarily involves modulation of glutamatergic neurotransmission and neurotrophic factor expression. After oral administration, Noopept is rapidly metabolized to cycloprolylglycine, its primary active metabolite, which mediates many of its central effects.
At the synaptic level, Noopept enhances AMPA receptor-mediated currents and modulates NMDA receptor sensitivity. AMPA receptor potentiation increases fast excitatory neurotransmission, which is critical for working memory, attention, and information processing speed. NMDA receptor modulation supports long-term potentiation (LTP), the cellular basis of memory formation and consolidation.
A distinguishing feature of Noopept is its ability to upregulate both BDNF and NGF expression in the hippocampus and cerebral cortex. BDNF supports neuronal survival, synaptic plasticity, and neurogenesis in adult brain regions critical for memory. NGF is essential for cholinergic neuron maintenance—the same neurons that degenerate in Alzheimer's disease. This neurotrophic action provides a mechanism for sustained cognitive improvement beyond acute receptor modulation.
Noopept also demonstrates significant antioxidant and anti-inflammatory properties. It reduces glutamate-induced excitotoxicity, decreases reactive oxygen species (ROS) accumulation, inhibits calcium-dependent apoptotic pathways, and suppresses microglial activation in neuroinflammatory models. These neuroprotective effects have made it a compound of interest in neurodegenerative disease research.
- AMPA receptor potentiation: Enhances fast excitatory transmission for improved attention and processing
- NMDA receptor modulation: Supports long-term potentiation and memory consolidation
- BDNF upregulation: Increases brain-derived neurotrophic factor in hippocampus and cortex
- NGF enhancement: Supports cholinergic neuron survival and function
- Antioxidant neuroprotection: Reduces ROS, glutamate excitotoxicity, and oxidative stress
- Anti-amyloid effect: Prevents beta-amyloid oligomer formation and toxicity in vitro
Pharmacokinetics
Pharmacokinetic data from Russian clinical studies and preclinical research.
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (Oral) | ~9.7% | Low oral bioavailability; sublingual may improve |
| Half-life | ~30–60 minutes (parent compound) | Short half-life; active metabolite has longer duration |
| Tmax | 15–20 minutes | Very rapid absorption and brain penetration |
| BBB penetration | Yes (lipophilic) | Rapidly crosses blood-brain barrier |
| Active metabolite | Cycloprolylglycine | Endogenous neuropeptide mediating sustained effects |
| Metabolism | Hepatic ester hydrolysis | Prodrug rapidly converted to active form |
Dosing & administration
The recommended dose in Russian clinical practice is 10–30 mg per day, divided into 2–3 doses. Most users take 10 mg twice daily (morning and afternoon), with the total daily dose not exceeding 30 mg. Due to its potency, doses above 30 mg are generally not recommended and may increase side effects.
Sublingual administration at 10 mg may improve bioavailability compared to oral swallowing. Noopept should be taken with food to reduce GI irritation. Cycling protocols of 1.5–3 months on, 1 month off are commonly recommended, though this is based on practitioner convention rather than clinical data.
Effects are typically noticed within 1–3 weeks of consistent use, with full cognitive benefits developing over 4–8 weeks as neurotrophic factor levels increase. This delayed onset distinguishes Noopept from acute stimulants.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Noopept has been prescribed in Russia since the early 2000s with a favorable safety record. Clinical trials at doses of 10–30 mg/day showed no significant adverse events compared to placebo. The compound has a very wide therapeutic index, with animal studies showing no toxicity at doses hundreds of times above the therapeutic range.
Common
- • Mild headache (usually resolves with choline supplementation)
- • Irritability at higher doses
- • Insomnia if taken late in the day
- • Mild gastrointestinal discomfort
- • Restlessness (dose-dependent)
- • Vivid dreams
Serious / potential risks
- • No serious adverse events reported in clinical trials at recommended doses
- • Potential for overstimulation of glutamate signaling at excessive doses
- • Unknown long-term safety with chronic use (years)
- • Theoretical concern for seizure threshold reduction at very high doses
- • Limited data on interactions with psychotropic medications
Drug interactions
Limited formal interaction studies; based on pharmacological mechanism.
| Medication | Interaction | Recommendation |
|---|---|---|
| Racetams (Piracetam, Aniracetam) | Overlapping glutamate modulation; potentially additive | May be combined at reduced doses; monitor for overstimulation |
| Choline sources (Alpha-GPC, CDP-Choline) | Synergistic; Noopept increases cholinergic demand | Commonly stacked together; choline may prevent headaches |
| Psychostimulants (Modafinil, Adderall) | Additive cognitive stimulation | Use with caution; may increase anxiety or restlessness |
| Anticonvulsants | Noopept modulates glutamate which affects seizure threshold | Consult neurologist; may alter seizure medication requirements |
| SSRIs/SNRIs | Both affect neurotrophic factors | Generally safe to combine; monitor for mood changes |
Storage & handling
Tablets/Capsules
- • Store at room temperature (15–25°C)
- • Protect from moisture and direct light
- • Keep in original blister packaging
- • Shelf life typically 3 years
Powder Form
- • Store in airtight container
- • Keep desiccant packet to absorb moisture
- • Stable at room temperature for 2+ years
- • Use milligram scale for accurate dosing
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Russian pharmacies (Noopept tablets) | $5–$15 per month | Approved medication in Russia; very affordable |
| International nootropic vendors | $15–$30 per month | Powder or capsule form; quality varies |
| Sublingual solutions | $20–$40 per month | Enhanced bioavailability formulations |
The bottom line
Noopept is a nootropic compound with research interest in cognition, neuroprotection, memory, bdnf. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying cognitive enhancement and neuroprotection
- • Individuals interested in cognition under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al.. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med (2008). doi: 10.1007/s10517-008-0297-x PMID: 19145356
- [2] Ostrovskaya RU, Gruden MA, Bobkova NA, et al.. The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. J Psychopharmacol (2007). doi: 10.1177/0269881106071335 PMID: 17092975
- [3] Gudasheva TA, Boyko SS, Akparov VK, et al.. Design of N-acylprolyldi peptides as neuroprotective agents. J Med Chem (1996).
- [4] Vakhitova YV, Sadovnikov SV, Borisevich SS, et al.. Molecular mechanism underlying the action of substituted pro-gly dipeptide noopept. Acta Naturae (2016). PMID: 27437132
- [5] Neznamov GG, Teleshova ES.. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol (2009). doi: 10.1007/s11055-009-9128-4 PMID: 19340573